ReviewRSC advances2025
Recent advances in nano vehicles encapsulating cinnamic acid and its derivatives as promising anticancer agents.
Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Exploring the mechanism of action of glaucocalyxin D against acute myeloid leukemia using network pharmacology, molecular docking and cellular experiments.Oncology letters · 2026Article
- Efficacy and safety of blinatumomab combination therapy in high-risk B-cell acute lymphoblastic leukemia: A systematic review and meta-analysis.Oncology letters · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although progress in cancer diagnosis and treatment has been substantial over recent decades, several challenges remain unresolved. Among these challenges are drug resistance, the recurrence of metastatic disease, off-target toxic effects, and nonselective drug targeting. In response, increasing attention has turned to naturally derived anticancer agents that may offer both efficacy and improved safety profiles. Among these, cinnamic acid, a phenylacrylic compound abundant in Lauraceae plants such as cinnamon, has shown remarkable antitumor activity against several cancer types. However, like many phytochemicals, its clinical utility is hampered by poor water solubility, low bioavailability, and unstable pharmacokinetics. In recent years, integrating nanotechnology into drug delivery strategies has opened new avenues for overcoming these limitations. This review explores the most recent developments in the nanoformulation of cinnamic acid and its derivatives, focusing on how nanocarriers may enhance their therapeutic potential in both
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.